The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The discovery of pathogenic germline variants in patients with myeloma
Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, discusses the discovery of pathogenic germline variants in around 8% of patients with multiple myeloma (MM). Many of the affected genes are part of the known causative genes for familial cancer syndromes, such as BRCA1 and BRCA2, and they all disrupt DNA repair mechanisms. Interestingly, patients with these mutations respond better to certain chemotherapies, such as alkylating agents, than patients without germline variants. Prof. Parekh suggests that screening pathways and specific treatment approaches can be developed for these patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
